肺纤维化
医学
纤维化
病态的
呼吸衰竭
病理
肺
弥漫性肺泡损伤
尸检
特发性肺纤维化
呼吸系统
免疫学
内科学
急性呼吸窘迫
作者
Shiqi Xiao,Tian-Zi Wen,Xinyu Chen,He-Yuan Chen,Zhuang Li,Zhi-Cheng He,Tao Luo,Rui Tang,Wenjuan Fu,Mianfu Cao,Lü Chen,Qin Niu,Shuai Wang,Lan Yang,Jia Ge,Qingrui Li,Haitao Guo,Yanxia Wang,Yi‐Fang Ping,Hong Shen
标识
DOI:10.1016/j.prp.2023.154920
摘要
Clinical data indicates that SARS-CoV-2 infection-induced respiratory failure is a fatal condition for severe COVID-19 patients. However, the pathological alterations of different types of respiratory failure remained unknown for severe COVID-19 patients. This study aims to evaluate whether there are differences in the performance of various types of respiratory failure in severe COVID-19 patients and investigate the pathological basis for these differences. The lung tissue sections of severe COVID-19 patients were assessed for the degree of injury and immune responses. Transcriptome data were used to analyze the molecular basis in severe COVID-19 patients. Severe COVID-19 patients with combined oxygenation and ventilatory failure presented more severe pulmonary fibrosis, airway obstruction, and prolonged disease course. The number of M2 macrophages increased with the degree of fibrosis in patients, suggesting that it may be closely related to the development of pulmonary fibrosis. The co-existence of pro-inflammatory and anti-inflammatory cytokines in the pulmonary environment could also participate in the progression of pulmonary fibrosis. Furthermore, the increased apoptosis in the lungs of COVID-19 patients with severe pulmonary fibrosis may represent a critical factor linking sustained inflammatory responses to fibrosis. Our findings indicate that during the extended phase of COVID-19, antifibrotic and antiapoptotic treatments should be considered in conjunction with the progression of the disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI